Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 19/20 | 0.62 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794396 | 1.00 | KCNQ2 (0.62) | KCNQ2KCNQ3HDAC6 | |
| SCHEMBL30795656 | 0.85 | KCNQ2 (0.44) | KCNQ2KCNQ3HDAC6 | |
| SCHEMBL693496 | 0.85 | KCNQ2 (0.44) | KCNQ2KCNQ3HDAC6 | |
| SCHEMBL23177866 | 0.82 | KCNQ2 (0.86) | KCNQ2KCNQ3 | |
| SCHEMBL30795574 | 0.81 | MAPT (0.49) | KCNQ2HDAC6 | |
| SCHEMBL693254 | 0.81 | MAPT (0.49) | KCNQ2HDAC6 | |
| SCHEMBL12703676 | 0.80 | KCNQ2 (0.57) | KCNQ2KCNQ3HDAC6 | |
| SCHEMBL2679556 | 0.79 | KCNQ2 (0.40) | KCNQ2HDAC6 | |
| SCHEMBL30795339 | 0.79 | KCNQ2 (0.40) | KCNQ2HDAC6 | |
| SCHEMBL2680190 | 0.78 | HDAC6 (0.40) | KCNQ2KCNQ3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-05-10 | — | — | US | claimed |
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| EP-2421863-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch AS (DK) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122064-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | KCNQ1, KCNQ2, KCNQ5 | KCNQ2 2/4885KCNQ3 5/4885HDAC6 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.